Oct 26, 2020|

JD Becomes Exclusive Online Platform Offering New TCM Diabetic Drug

Share:

by Vivian Yang

JD Pharmacy has become the first and exclusive online platform to offer Mulberry Twig Alkaloids Tablets (桑枝总生物碱), an innovative hypoglycemic natural drug developed for type 2 diabetes patients through the collective efforts of traditional Chinese medicine (TCM) institutions and Chinese experts.

Online platforms are an emerging channel for diabetes patients’ health management. According to JD’s big data, over 10 million people bought or searched for diabetes-related products on JD’s platform in 2019. Among them, over 1 million people opted to receive an online medical consultation through JD Health’s telemedicine services. Thanks to the platform’s handy functions, 20 patients use JD’s platform to seek help on diabetes-related questions every single minute, on average.

The successful development of Mulberry Twig Alkaloids Tablets is regarded as a landmark breakthrough for TCM’s national science and technology project. The pills were approved for sales by the State Drug Administration in March 2020, the first approved TCM medicine for diabetes in the past 10 years.

The scientist, JD's Hui Zhou, told attendees at Augmented World Expo 2017 (AWE)

As the exclusive online sales channel of the new medicine, JD Health also reached a cooperation agreement with the sales permit holder “Beijing Wehand-Bio Pharmaceutical Co., LTD”. Both sides will work together to explore internet-based diabetes treatment in the future, such as in the areas of post-diagnosis health management, follow-up services, and more.

JD Health launched its diabetes center in April 2020. The center leverages JD’s strong technology capabilities in artificial intelligence, big data, and the Internet of things, combined with the online consultation, prescription purchase, and drug delivery capabilities of JD Internet Hospital to develop a closed-loop, integrated online and offline, diabetes management mechanism.

 

(vivian.yang@jd.com)

Share: